Completed PHASE2 INTERVENTIONAL 1-arm NCT00176228

Lamotrigine Monotherapy in Pediatric Bipolar Disorder

Open Trial of Lamotrigine Monotherapy in Pediatric Bipolar Disorder

Sponsor: GlaxoSmithKline

Interventions Lamotrigine

Updated 7 times since 2017 Last updated: Jul 28, 2015 Started: Feb 29, 2004 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00176228, this PHASE2 trial focuses on Bipolar Disorder and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University of Illinois at Chicago

Data source: University of Illinois at Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States